$NGNE
Neurogene Inc. Stock $ngne

$ngne Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000119312515280995 Filed on August 06, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.230M	$1.170M	$1.080M
YoY Change	24.24%	8.33%	191.89%
% of Gross Profit
Research & Development	$3.687M	$3.619M	$4.551M
YoY Change	-30.73%	-20.48%	264.93%
% of Gross Profit
Depreciation & Amortization			$71.94K
YoY Change			361.38%
% of Gross Profit
Operating Expenses	$4.917M	$4.792M	$5.632M
YoY Change	-22.08%	-14.91%	248.33%
Operating Profit
YoY Change
Interest Expense	$4.000K	$5.000K	$2.000K
YoY Change	100.0%	150.0%	13.06%
% of Operating Profit
Other Income/Expense, Net	-$118.0K	$42.00K	$208.0K
YoY Change	-553.85%	-79.81%	-74.17%
Pretax Income	-$5.035M	-$4.750M	-$5.424M
YoY Change	-19.88%	-12.43%	568.39%
Income Tax
% Of Pretax Income
Net Earnings	-$5.035M	-$4.750M	-$5.424M
YoY Change	-19.88%	-12.43%	568.39%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$425.7K	-$443.1K	-$507.5K
COMMON SHARES
Basic Shares Outstanding	10.73M shares	10.72M shares	10.68M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$117.4M	$29.00M	$35.90M
YoY Change	193.5%	-19.22%
Cash & Equivalents	$109.4M	$14.92M	$17.90M
Short-Term Investments	$8.000M	$14.10M	$18.00M
Other Short-Term Assets	$500.0K	$700.0K	$400.0K
YoY Change	66.67%	75.0%
Inventory
Prepaid Expenses			$424.2K
Receivables	$0.00	$100.0K	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$117.9M	$29.76M	$36.34M
YoY Change	192.18%	-18.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$81.00K	$85.00K	$116.9K
YoY Change	-16.99%	-27.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$16.50M
YoY Change	-100.0%	-100.0%
Other Assets	$12.00K	$12.00K	$16.77K
YoY Change	-13.44%	-28.42%
Total Long-Term Assets	$93.00K	$97.00K	$16.62M
YoY Change	-98.87%	-99.42%
TOTAL ASSETS
Total Short-Term Assets	$117.9M	$29.76M	$36.34M
Total Long-Term Assets	$93.00K	$97.00K	$16.62M
Total Assets	$118.0M	$29.86M	$52.96M
YoY Change	142.78%	-43.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.900M	$4.000M	$2.800M
YoY Change	-15.22%	42.86%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change
Total Short-Term Liabilities	$3.859M	$3.983M	$2.846M
YoY Change	-15.59%	39.95%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%
Total Long-Term Liabilities	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.859M	$3.983M	$2.846M
Total Long-Term Liabilities	$100.0K	$100.0K	$100.0K
Total Liabilities	$4.001M	$4.049M	$2.939M
YoY Change	-13.69%	37.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$105.6M	-$100.6M	-$75.04M
YoY Change	29.87%	34.03%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$114.0M	$25.81M	$50.02M
YoY Change
Total Liabilities & Shareholders Equity	$118.0M	$29.86M	$52.96M
YoY Change	142.78%	-43.62%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$5.035M	-$4.750M	-$5.424M
YoY Change	-19.88%	-12.43%	568.39%
Depreciation, Depletion And Amortization			$71.94K
YoY Change			361.38%
Cash From Operating Activities	-$4.210M	-$5.800M	-$2.810M
YoY Change	0.72%	106.41%	95.14%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	$0.00	$64.61K
YoY Change	-50.0%	-100.0%	2446.75%
Acquisitions
YoY Change
Other Investing Activities	$6.070M	$6.020M	-$31.76M
YoY Change	173.42%	-118.95%	-28972.73%
Cash From Investing Activities	$6.060M	$6.030M	-$31.83M
YoY Change	174.21%	-118.94%	-31930.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	93.08M	-50.00K	-390.0K
YoY Change	-186260.0%	-87.18%	333.33%
NET CHANGE
Cash From Operating Activities	-4.210M	-5.800M	-2.810M
Cash From Investing Activities	6.060M	6.030M	-31.83M
Cash From Financing Activities	93.08M	-50.00K	-390.0K
Net Change In Cash	94.93M	180.0K	-35.03M
YoY Change	-4799.5%	-100.51%	2349.65%
FREE CASH FLOW
Cash From Operating Activities	-$4.210M	-$5.800M	-$2.810M
Capital Expenditures	-$10.00K	$0.00	$64.61K
Free Cash Flow	-$4.200M	-$5.800M	-$2.875M
YoY Change	0.96%	101.77%	99.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10727221	shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3044000
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17896000
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	0
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1067799	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.24
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10727221	shares
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	509192	shares
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10727221	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.60
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.000001
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	25810000
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	126383000
CY2015Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	66000
CY2015Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3983000
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-100577000
CY2015Q2	us-gaap	Liabilities Liabilities	4049000
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29859000
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3983000
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4000
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	379000
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12000
CY2015Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4166000
CY2015Q2	us-gaap	Assets Assets	29859000
CY2015Q2	us-gaap	Cash Cash	3633000
CY2015Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	72000
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	85000
CY2015Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	14109000
CY2015Q2	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	0
CY2015Q2	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	14043000
CY2015Q2	us-gaap	Assets Current AssetsCurrent	29762000
CY2015Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	11283000
CY2015Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	87000
CY2015Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	14109000
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	0
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14916000
CY2015Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	14105000
CY2015Q2	aqxp	Prepayments And Deposits Current PrepaymentsAndDepositsCurrent	578000
CY2015Q2	aqxp	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedAggregateIntrinsicValue	0
CY2015Q2	aqxp	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue	425000
CY2015Q2	aqxp	Stock Shares Authorized Net StockSharesAuthorizedNet	55000000	shares
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11006000
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5203000
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-89416000
CY2014Q4	us-gaap	Liabilities Liabilities	5275000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	41422000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	0
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	824604	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.79
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10695108	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000001
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10695108	shares
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	36147000
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	125567000
CY2014Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	72000
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5203000
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13000
CY2014Q4	us-gaap	Assets Assets	41422000
CY2014Q4	us-gaap	Cash Cash	8351000
CY2014Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	65000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	105000
CY2014Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	24191000
CY2014Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	2003000
CY2014Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	26122000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	39301000
CY2014Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	6555000
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	24191000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14906000
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	24195000
CY2014Q4	aqxp	Prepayments And Deposits Current PrepaymentsAndDepositsCurrent	139000
CY2014Q4	aqxp	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	2003000
CY2014Q4	aqxp	Available For Sale Securities Debt Maturities After One Through Two Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost	2003000
CY2014Q4	aqxp	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue	789000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6609000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0167	pure
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.43
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	817022	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.08	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.42
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6606091	shares
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	268000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5201000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1406000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9652000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9653000
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	928000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	34475000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-196000
	us-gaap	Share Based Compensation ShareBasedCompensation	352000
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	20000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6890000
	us-gaap	Operating Expenses OperatingExpenses	8247000
	us-gaap	Interest Expense InterestExpense	456000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M9D
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	69000
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	5000
	us-gaap	Net Income Loss NetIncomeLoss	-9653000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9447000
	us-gaap	Repayments Of Debt RepaymentsOfDebt	2600000
	us-gaap	Interest Paid InterestPaid	32000
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	186000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-31830000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	45329000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6431000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1207000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	352000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1816000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	320000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	2714000
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	53130000
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	50000
	aqxp	Fee And Penalty On Bank Loan Repayment FeeAndPenaltyOnBankLoanRepayment	100000
	aqxp	Amortization Of Preferred Stock Discount AmortizationOfPreferredStockDiscount	1884000
	aqxp	Share Issuance Expenditures Incurred But Not Yet Paid ShareIssuanceExpendituresIncurredButNotYetPaid	50000
	aqxp	Adjustments For Temporary Equity Accretion Liquidation Preference AdjustmentsForTemporaryEquityAccretionLiquidationPreference	1133000
	aqxp	Income Tax Expense On Preferred Stock IncomeTaxExpenseOnPreferredStock	100000
	aqxp	Reversal Of Income Tax Payable On Preferred Stock ReversalOfIncomeTaxPayableOnPreferredStock	1898000
	aqxp	Extinguishment Of Remaining Share Issuance Costs Due To Conversion Of Preferred Stock ExtinguishmentOfRemainingShareIssuanceCostsDueToConversionOfPreferredStock	439000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1. Nature of operations</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Aquinox Pharmaceuticals, Inc. and its wholly owned subsidiary, Aquinox Pharmaceuticals (Canada) Inc., (consolidated, the “Company”) is a clinical stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Aquinox Pharmaceuticals (USA) Inc. was incorporated on May 31, 2007 in the State of Delaware, United States. On January 27, 2014, Aquinox Pharmaceuticals (USA) Inc. changed its name to Aquinox Pharmaceuticals, Inc. (“Aquinox USA”).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Aquinox Pharmaceuticals (Canada) Inc. (“AQXP Canada”) was originally incorporated under the name of 6175813 Canada Inc. on December 26, 2003 under the Canada Business Corporations Act. In May 2014, after a corporate restructuring, the name was changed to Aquinox Pharmaceuticals (Canada) Inc.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The Company operates in Vancouver, British Columbia, Canada.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12098000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	12442	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4M24D
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0147	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.04
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1079162	shares
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001404644
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M29D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M28D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	8.34
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.98	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.42
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Registrant Name EntityRegistrantName	AQUINOX PHARMACEUTICALS, INC
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.98
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.02
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>(b) Use of estimates and assumptions</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring management estimates are the valuation of stock options and warrants, amortization and depreciation, accrual of expenses, valuation allowance for deferred income taxes, and contingencies. Actual results could differ from those estimates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The accompanying financial statements have been prepared under the assumption that the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The eventual profitability of the Company and its ability to continue as a going concern is dependent upon many factors, including its ability to obtain sufficient financing, the successful development of its product candidates, and receiving regulatory approvals. The Company’s cash resources are sufficient, in management’s opinion, to support its current operations for the next 12 months. However, the Company will need to raise substantial financing in the future to continue funding its operations. In order to meet its cash requirements, the Company may seek to sell additional equity or convertible debt securities that may result in dilution to stockholders. If the Company raises additional funds through the issuance of convertible debt securities, these securities could have rights senior to common stockholders and could contain restrictive covenants. There can be no assurance that additional equity or debt financing will be available or available on terms acceptable to the Company, if at all. Failure to obtain sufficient funds on acceptable terms when needed could have a negative impact on the Company’s business, results of operations, financial condition, cash flows and future prospects.</p> </div>
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	32113	shares
	dei	Trading Symbol TradingSymbol	AQXP
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10717808	shares
	aqxp	Common Stock Reserved For Issuance Description CommonStockReservedForIssuanceDescription	Additionally, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year for a period of up to 10 years, beginning on January 1, 2015 and ending on and including January 1, 2024, by 4% of the total number of shares of capital outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the board of directors.
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y11M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	287750	shares
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	7000
	us-gaap	Net Income Loss NetIncomeLoss	-11162000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11162000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	438000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	76000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-326000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-330000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	8000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11154000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11162000
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	6000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-26000
	us-gaap	Share Based Compensation ShareBasedCompensation	721000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	10000
	us-gaap	Operating Expenses OperatingExpenses	10832000
	us-gaap	Interest Expense InterestExpense	10000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	12088000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	20000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8186000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1232000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	96000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	721000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2646000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	12094000
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	27000
	aqxp	Share Based Compensation Arrangement By Share Based Payment Award Options Expired Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredAggregateIntrinsicValue	0
	aqxp	Share Issuance Expenditures Incurred But Not Yet Paid ShareIssuanceExpendituresIncurredButNotYetPaid	11000
	aqxp	Period Shares Reserved For Issuance Will Increase PeriodSharesReservedForIssuanceWillIncrease	P10Y
	aqxp	Fair Value Transfers Between Level One Level Two And Level Three Amount FairValueTransfersBetweenLevelOneLevelTwoAndLevelThreeAmount	0
	aqxp	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAggregateIntrinsicValue	0
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	215000
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1081000
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	aqxp	Stock Based Compensation Increase In Common Stock Issuance Percentage StockBasedCompensationIncreaseInCommonStockIssuancePercentage	0.04	pure
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M28D
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5423000
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5424000
CY2014Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	14000
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	5632000
CY2014Q2	us-gaap	Interest Expense InterestExpense	2000
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4551000
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0170	pure
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	641522	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.08	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.30
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10675260	shares
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-5424000
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5424000
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	196000
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	208000
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0125	pure
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1068255	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.95	pure
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.69
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10723584	shares
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-4750000
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4750000
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	34000
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	42000
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4749000
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4750000
CY2015Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	13000
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	4792000
CY2015Q2	us-gaap	Interest Expense InterestExpense	5000
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3619000
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	455000
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1173000
CY2015Q2	aqxp	Fair Value Transfers Between Level One Level Two And Level Three Amount FairValueTransfersBetweenLevelOneLevelTwoAndLevelThreeAmount	0

Files In Submission

Name	View Source	Status
0001193125-15-280995-index-headers.html	Edgar Link	pending
0001193125-15-280995-index.html	Edgar Link	pending
0001193125-15-280995.txt	Edgar Link	pending
0001193125-15-280995-xbrl.zip	Edgar Link	pending
aqxp-20150630.xml	Edgar Link	completed
aqxp-20150630.xsd	Edgar Link	pending
aqxp-20150630_cal.xml	Edgar Link	unprocessable
aqxp-20150630_def.xml	Edgar Link	unprocessable
aqxp-20150630_lab.xml	Edgar Link	unprocessable
aqxp-20150630_pre.xml	Edgar Link	unprocessable
d941993d10q.htm	Edgar Link	pending
d941993dex311.htm	Edgar Link	pending
d941993dex312.htm	Edgar Link	pending
d941993dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NGNE
Neurogene Inc. Stock $ngne

2015 Q3 Form 10-Q Financial Statement

#000119312515280995 Filed on August 06, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NGNE Neurogene Inc. Stock $ngne

2015 Q3 Form 10-Q Financial Statement

#000119312515280995 Filed on August 06, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NGNE
Neurogene Inc. Stock $ngne